NO20092662L - Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme - Google Patents
Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det sammeInfo
- Publication number
- NO20092662L NO20092662L NO20092662A NO20092662A NO20092662L NO 20092662 L NO20092662 L NO 20092662L NO 20092662 A NO20092662 A NO 20092662A NO 20092662 A NO20092662 A NO 20092662A NO 20092662 L NO20092662 L NO 20092662L
- Authority
- NO
- Norway
- Prior art keywords
- physiologically active
- producing
- same
- release composition
- lactic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gynecology & Obstetrics (AREA)
- Nanotechnology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Peptides Or Proteins (AREA)
Abstract
Sammensetningen med opprettholdt frigjøring hvor et vannløselig, fysiologisk aktivt peptid hovedsakelig er uniformt dispergert i en mikrokapsel bestående av en melkesyrepolymer eller et salt derav, og den fysiologisk aktive substansen er inneholdt i en mengde på 15 til 35 vekt % i forhold til de totale mikrokapslene og vektgjennomsnittlig molekylær vekt av melkesyrepolymeren er omkring I 1 000 til omkring 27 000, som er karakterisert ved å ha et høyt innehold av den fysiologisk aktive substansen, og undertrykkelse av den initiale overdrevne frigjøringen innenfor én dag etter administrasjonen og en stabil opprettholdt medikamentfrigjøring over en lang tidsperiode, og fremgangsmåte for å produsere det samme.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87536406P | 2006-12-18 | 2006-12-18 | |
US91740107P | 2007-05-11 | 2007-05-11 | |
PCT/JP2007/074617 WO2008075762A1 (en) | 2006-12-18 | 2007-12-17 | Sustained-release composition and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20092662L true NO20092662L (no) | 2009-09-07 |
NO347209B1 NO347209B1 (no) | 2023-07-03 |
Family
ID=39015849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092662A NO347209B1 (no) | 2006-12-18 | 2007-12-17 | Sammensetning med forlenget frigjøring og fremgangsmåte for å produsere det samme |
Country Status (27)
Country | Link |
---|---|
US (3) | US8921326B2 (no) |
EP (1) | EP2094246B1 (no) |
JP (2) | JP4564098B2 (no) |
KR (1) | KR101522035B1 (no) |
CN (1) | CN101563068B (no) |
AR (1) | AR064381A1 (no) |
AU (1) | AU2007335406B2 (no) |
BR (1) | BRPI0720582B1 (no) |
CA (1) | CA2671670C (no) |
CL (1) | CL2007003658A1 (no) |
CO (1) | CO6180498A2 (no) |
CR (1) | CR10867A (no) |
DO (1) | DOP2009000144A (no) |
EA (1) | EA016176B1 (no) |
EC (1) | ECSP099439A (no) |
ES (1) | ES2791698T3 (no) |
GE (1) | GEP20125597B (no) |
IL (1) | IL198845A (no) |
MA (1) | MA31006B1 (no) |
MX (1) | MX2009006653A (no) |
MY (1) | MY148370A (no) |
NO (1) | NO347209B1 (no) |
NZ (1) | NZ577281A (no) |
PE (1) | PE20081842A1 (no) |
TN (1) | TN2009000197A1 (no) |
TW (1) | TWI481424B (no) |
WO (1) | WO2008075762A1 (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009006653A (es) | 2006-12-18 | 2009-07-02 | Takeda Pharmaceutical | Composicion de liberacion prolongada y metodo para producirla. |
PE20121481A1 (es) * | 2009-12-22 | 2012-11-12 | Takeda Pharmaceutical | Formulacion de liberacion sostenida |
WO2011162413A1 (en) * | 2010-06-25 | 2011-12-29 | Takeda Pharmaceutical Company Limited | Sustained-release formulation |
US20150087624A1 (en) * | 2012-04-24 | 2015-03-26 | Osaka University | Method for producing an aqueous dispersion of drug nanoparticles and use thereof |
KR101558083B1 (ko) * | 2014-04-07 | 2015-10-07 | 에스케이케미칼주식회사 | 약물함유 고분자미립구 제조방법 |
WO2015158823A1 (de) | 2014-04-16 | 2015-10-22 | Veyx-Pharma Gmbh | Veterinärpharmazeutische zusammensetzung und deren verwendung |
TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
CA3077011A1 (en) * | 2017-09-26 | 2019-04-04 | Nanomi B.V. | Method for preparing micro-particles by double emulsion technique |
KR101936040B1 (ko) * | 2018-04-23 | 2019-01-08 | 주식회사 씨트리 | 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법 |
JP7066913B2 (ja) | 2019-03-26 | 2022-05-13 | ノベルファーマ株式会社 | 持続型脂肪酸結合GnRH誘導体及びこれを含む薬剤学的組成物 |
WO2021010719A1 (ko) * | 2019-07-12 | 2021-01-21 | 주식회사 지투지바이오 | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3297033A (en) | 1963-10-31 | 1967-01-10 | American Cyanamid Co | Surgical sutures |
US3565869A (en) | 1968-12-23 | 1971-02-23 | American Cyanamid Co | Extrudable and stretchable polyglycolic acid and process for preparing same |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3755558A (en) | 1971-02-23 | 1973-08-28 | Du Pont | Polylactide drug mixtures for topical application atelet aggregation |
US3839297A (en) | 1971-11-22 | 1974-10-01 | Ethicon Inc | Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures |
US3912692A (en) | 1973-05-03 | 1975-10-14 | American Cyanamid Co | Process for polymerizing a substantially pure glycolide composition |
US3890283A (en) | 1973-06-04 | 1975-06-17 | American Cyanamid Co | Process for post-polymerizing polyglycolic acid |
US4258063A (en) | 1978-06-23 | 1981-03-24 | Henkel Corporation | Self-emulsifying cosmetic base |
US4249531A (en) | 1979-07-05 | 1981-02-10 | Alza Corporation | Bioerodible system for delivering drug manufactured from poly(carboxylic acid) |
US4273920A (en) | 1979-09-12 | 1981-06-16 | Eli Lilly And Company | Polymerization process and product |
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
US5366734A (en) | 1981-02-16 | 1994-11-22 | Zeneca Limited | Continuous release pharmaceutical compositions |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4479911A (en) | 1982-01-28 | 1984-10-30 | Sandoz, Inc. | Process for preparation of microspheres and modification of release rate of core material |
US4605730A (en) | 1982-10-01 | 1986-08-12 | Ethicon, Inc. | Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same |
US4539981A (en) | 1982-11-08 | 1985-09-10 | Johnson & Johnson Products, Inc. | Absorbable bone fixation device |
FR2537980B1 (fr) | 1982-12-17 | 1986-12-19 | Sandoz Sa | Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation |
CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
JPH0678425B2 (ja) | 1984-07-06 | 1994-10-05 | 和光純薬工業株式会社 | 重合体の新規製造法 |
CA1236641A (en) | 1984-07-06 | 1988-05-10 | Motoaki Tanaka | Copolymer of lactic acid and glycolic acid and method for producing same |
EP0190833B1 (en) | 1985-02-07 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Method for producing microcapsule |
JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
JP2653255B2 (ja) | 1990-02-13 | 1997-09-17 | 武田薬品工業株式会社 | 長期徐放型マイクロカプセル |
MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
FR2658432B1 (fr) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
CA2040141C (en) | 1990-04-13 | 2002-05-14 | Minoru Yamada | Biodegradable high-molecular polymers, production and use therof |
JP3116311B2 (ja) | 1990-06-13 | 2000-12-11 | エーザイ株式会社 | マイクロスフィアの製法 |
FR2693905B1 (fr) | 1992-07-27 | 1994-09-02 | Rhone Merieux | Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues. |
ES2110573T3 (es) | 1992-08-07 | 1998-02-16 | Takeda Chemical Industries Ltd | Produccion de microcapsulas de farmacos solubles en agua. |
JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
DE4342092B4 (de) | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
JP3490171B2 (ja) | 1994-02-21 | 2004-01-26 | 武田薬品工業株式会社 | 生体内分解性ポリマーの末端カルボキシル基におけるエステル |
EP0668073B1 (en) | 1994-02-21 | 1999-04-14 | Takeda Chemical Industries, Ltd. | Polyester matrix for a pharmaceutical sustained-release preparation |
JPH07273447A (ja) | 1994-03-29 | 1995-10-20 | Sumitomo Kinzoku Ceramics:Kk | セラミック回路基板及びその製造方法 |
US5763513A (en) | 1994-05-19 | 1998-06-09 | Mitsui Toatsu Chemicals, Inc. | L-lactic acid polymer composition, molded product and film |
FR2736508B1 (fr) | 1995-07-13 | 1997-09-19 | Francais Prod Ind Cfpi | Nouvelle forme solide de stockage et de commercialisation pour compositions phytosanitaires et moyens pour sa preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
CA2192773C (en) | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
JPH10273447A (ja) | 1997-01-29 | 1998-10-13 | Takeda Chem Ind Ltd | 徐放性マイクロスフィア、その製造法および用途 |
AU5678398A (en) | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
US5945126A (en) | 1997-02-13 | 1999-08-31 | Oakwood Laboratories L.L.C. | Continuous microsphere process |
GB9718986D0 (en) | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
JPH11269094A (ja) | 1998-01-16 | 1999-10-05 | Takeda Chem Ind Ltd | 徐放性組成物、その製造法および用途 |
SK10272000A3 (sk) * | 1998-01-16 | 2001-01-18 | Takeda Chemical Industries, Ltd. | Prostriedok s trvalým uvoľňovaním, spôsob jeho výroby a jeho použitia |
SK11902000A3 (sk) | 1998-03-04 | 2001-02-12 | Takeda Chemical Industries, Ltd. | Prostriedok s predĺženým uvoľňovaním pre antagonistu angiotenzínu ii, jeho príprava a použitie |
US6114495A (en) | 1998-04-01 | 2000-09-05 | Cargill Incorporated | Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof |
US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
US6270802B1 (en) | 1998-10-28 | 2001-08-07 | Oakwood Laboratories L.L.C. | Method and apparatus for formulating microspheres and microcapsules |
AU1797800A (en) | 1998-12-15 | 2000-07-03 | Takeda Chemical Industries Ltd. | Process for producing polymer |
NZ516466A (en) | 1999-07-15 | 2003-02-28 | Takeda Chemical Industries Ltd | Sustained release compositions, process for producing the same and use thereof |
AU6510400A (en) | 1999-08-04 | 2001-03-05 | Oakwood Laboratories L.L.C. | Slow release microspheres |
AU2001276733A1 (en) | 2000-08-07 | 2002-02-18 | Takeda Chemical Industries Ltd. | Lactic acid polymer and process for producing the same |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
AU2002218494A1 (en) | 2000-11-29 | 2002-06-11 | Takeda Chemical Industries Ltd. | Medicinal compositions and process for producing the same |
AU2002221139A1 (en) | 2000-12-15 | 2002-06-24 | Takeda Chemical Industries Ltd. | Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof |
TWI332407B (en) | 2001-06-29 | 2010-11-01 | Takeda Chemical Industries Ltd | Controlled release composition and method of producting the same |
TWI225416B (en) | 2001-06-29 | 2004-12-21 | Takeda Chemical Industries Ltd | Sustained-release composition and process for producing the same |
WO2003055470A1 (fr) | 2001-12-26 | 2003-07-10 | Takeda Chemical Industries, Ltd. | Nouvelle microsphere et son procede de production |
CN1662260B (zh) * | 2002-06-25 | 2010-04-28 | 武田药品工业株式会社 | 缓释组合物的制备方法 |
US6803708B2 (en) * | 2002-08-22 | 2004-10-12 | Cdream Display Corporation | Barrier metal layer for a carbon nanotube flat panel display |
CA2533314C (en) * | 2003-07-18 | 2013-07-09 | Oakwood Laboratories, L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
ES2741576T3 (es) | 2003-07-23 | 2020-02-11 | Evonik Corp | Composiciones de liberación controlada |
JP2007537137A (ja) * | 2003-09-24 | 2007-12-20 | モンタナ ステート ユニバーシティ | ノロウィルスモノクローナル抗体及びペプチド |
TW200613012A (en) * | 2004-07-02 | 2006-05-01 | Takeda Pharmaceuticals Co | Sustained-release composition, process for producing the same and use of the same |
KR101341359B1 (ko) | 2004-10-01 | 2013-12-13 | 램스코르 인코포레이티드 | 편리하게 이식가능한 서방형 약물 조성물 |
AU2005304435B8 (en) | 2004-11-10 | 2011-06-23 | Tolmar Therapeutics, Inc. | A stabilized polymeric delivery system |
MX2009006653A (es) | 2006-12-18 | 2009-07-02 | Takeda Pharmaceutical | Composicion de liberacion prolongada y metodo para producirla. |
-
2007
- 2007-12-17 MX MX2009006653A patent/MX2009006653A/es active IP Right Grant
- 2007-12-17 KR KR1020097011993A patent/KR101522035B1/ko active IP Right Review Request
- 2007-12-17 US US12/312,751 patent/US8921326B2/en active Active
- 2007-12-17 CN CN2007800469578A patent/CN101563068B/zh active Active
- 2007-12-17 TW TW096148177A patent/TWI481424B/zh active
- 2007-12-17 AR ARP070105656A patent/AR064381A1/es not_active Application Discontinuation
- 2007-12-17 EA EA200970600A patent/EA016176B1/ru not_active IP Right Cessation
- 2007-12-17 JP JP2009524632A patent/JP4564098B2/ja active Active
- 2007-12-17 BR BRPI0720582-1A patent/BRPI0720582B1/pt active IP Right Grant
- 2007-12-17 MY MYPI20092544A patent/MY148370A/en unknown
- 2007-12-17 CA CA2671670A patent/CA2671670C/en not_active Expired - Fee Related
- 2007-12-17 EP EP07859925.5A patent/EP2094246B1/en active Active
- 2007-12-17 ES ES07859925T patent/ES2791698T3/es active Active
- 2007-12-17 NZ NZ577281A patent/NZ577281A/en unknown
- 2007-12-17 WO PCT/JP2007/074617 patent/WO2008075762A1/en active Application Filing
- 2007-12-17 NO NO20092662A patent/NO347209B1/no unknown
- 2007-12-17 AU AU2007335406A patent/AU2007335406B2/en active Active
- 2007-12-17 CL CL200703658A patent/CL2007003658A1/es unknown
- 2007-12-17 GE GEAP200711311A patent/GEP20125597B/en unknown
-
2008
- 2008-01-02 PE PE2008000035A patent/PE20081842A1/es active IP Right Grant
-
2009
- 2009-05-20 IL IL198845A patent/IL198845A/en active IP Right Grant
- 2009-05-20 TN TNP2009000197A patent/TN2009000197A1/fr unknown
- 2009-06-12 CR CR10867A patent/CR10867A/es unknown
- 2009-06-17 EC EC2009009439A patent/ECSP099439A/es unknown
- 2009-06-17 MA MA32010A patent/MA31006B1/fr unknown
- 2009-06-17 DO DO2009000144A patent/DOP2009000144A/es unknown
- 2009-06-18 CO CO09063558A patent/CO6180498A2/es not_active Application Discontinuation
-
2010
- 2010-06-07 JP JP2010130277A patent/JP5258844B2/ja active Active
-
2014
- 2014-11-19 US US14/547,467 patent/US9617303B2/en active Active
-
2017
- 2017-02-28 US US15/444,712 patent/US9713595B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20092662L (no) | Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme | |
US10668014B2 (en) | Method and system for preventing sore throat in humans | |
US11357722B2 (en) | Method and system for preventing sore throat in humans | |
RU2005115855A (ru) | Композиция трамадола продлонгированного высвобождением с 24-часовым действием | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
DE69940735D1 (de) | Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen | |
WO2014186937A1 (zh) | 贻贝粘蛋白凝胶的制备方法、贻贝粘蛋白凝胶及其应用 | |
KR101747411B1 (ko) | 신경전달물질을 조절하는 펩타이드의 신경세포 전달용 용해성 미세바늘 | |
FR2811571B1 (fr) | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif | |
CA2253980A1 (en) | Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof | |
MY151468A (en) | Controlled release solid preparation | |
EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
MY151470A (en) | Controlled release solid preparation | |
US20160015735A1 (en) | Anti-microbial composition | |
GEP20043285B (en) | Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections | |
NO20055601L (no) | Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer | |
AU2020203126B2 (en) | Pharmaceutical solution comprising dopamine for use in treating Parkinson's disease | |
WO2004078111A3 (en) | Extended release minocycline compositions and processes for their preparation | |
Algin-Yapar | Nasal inserts for drug delivery: an overview | |
ATE355833T1 (de) | Pharmazeutische polymerformulierung zur retardierten freisetzung von terbutalinsulfat | |
UA97125C2 (ru) | Композиция продолжительного высвобождения и способ ее получения | |
FR3097740A1 (fr) | Bactérie de la famille des Christensenellacées et composition en contenant pour la prévention et/ou le traitement d’une perte de masse musculaire pathologique ou d’une maladie caractérisée par une perte de masse musculaire pathologique | |
PL214226B1 (pl) | Preparat zawierajacy podstawione pochodne imidazolu | |
JP2014070061A5 (no) | ||
RS20060413A (en) | Non-disintegrating oral solid composition of high dose of water soluble drugs |